Stage of change of cigarette smoking in drug dependent patients

Résumé En Suisse, les programmes de désaccoutumance au tabac se réfèrent généralement au modèle de préparation au changement de Prochaska et DiClemente (1983), Les patients atteints de maladies somatiques liées au tabagisme comme les pathologies cardiovasculaires ou pulmonaires accèdent facilement à ces programmes, contrairement aux patients présentant une dépendance à des drogues illicites. La prévalence de fumeurs dans cette population est pourtant élevée et les problèmes engendrés par le tabac sont importants, non seulement d'un point de vue individuel mais aussi en terme de santé publique. Il est par conséquent intéressant d'évaluer la motivation concernant la désaccoutumance au tabac de patients toxicomanes entreprenant un sevrage de drogues illicites. Dans cette étude, nous avons évalué les stades de préparation au changement concernant la dépendance au tabac chez 100 patients toxicomanes hospitalisés sur un mode volontaire dans le cadre d'un programme de sevrage à des drogues illégales. L'évaluation s'est faite à l'aide d'un auto-questionnaire dont les résultats indiquent qu'une minorité de patients sont décidés à interrompre la consommation de tabac. En effet, seul 15% des patients se trouvaient aux stades de contemplation ou de décision. De plus, 93% des sujets considéraient l'arrêt du tabac comme difficile ou très difficile. Ces données montrent qu'il existe un décalage important entre la motivation relative au sevrage de drogues illégales et la motivation liées à l'arrêt du tabac. En effet, malgré leur motivation élevée pour se sevrer de drogues illicites, la proportion de patients restant au stade de précontemplation concernant la désaccoutumance au tabac reste élevée. Diverses hypothèses permettent d'expliquer ces résultats, notamment la perception que la désaccoutumance au tabac est plus difficile à réaliser que le sevrage de substances illicites. Abstract Nicotine cessation programmes in Switzerland, which are commonly based on the stage of change model of Prochaska and DiClemente (1983), are rarely offered to patients with illicit drug dependence. This stands in contrast to the high smoking rates and the heavy burden of tobacco-related problems in these patients. The stage of change was therefore assessed by self-administered questionnaire in 100 inpatients attending an illegal drug withdrawal programme. Only 15% of the patients were in the contemplation or decision stage. 93% considered smoking cessation to be difficult or very difficult. These data show a discrepancy between the motivation to change illegal drug consumption habits and the motivation for smoking cessation. The high pro-portion of patients remaining in the precontemplation stage for smoking cessation, in spite of their motivation for illicit drug detoxification, may be due to the perception that cessation of smoking is more difficult than illicit drug abuse cessation.

R&D cooperation between Spanish firms and scientific partners: what is the role of tertiary education?

This paper explores the factors that determine firm’s R&D cooperation with different partners, paying special attention on the role of tertiary education (degree and PhDs level) in facilitating the connection between the firms and the to scientific bodies (technology centres, public research centres and universities). Here, we attempt to answer two questions. First, are innovative firms that carry out internal and external R&D activities more likely to cooperate on R&D projects with other partners? Second, do Spanish innovative firms with a high participation of researchers with degrees or PhDs tend to cooperate more with scientific partners? To answer both questions we apply a three-dimensional approach on a firm level Panel Data with a sample of 4.998 manufacturing and services Spanish firms. First, we run a complementary test between external R&D acquisition and skilled research workers and find that firms which carry out external R&D activities obtain a greater return on R&D cooperation when they have skilled workers in R&D, especially in high-tech manufactures and KIS services. Second, we carry out a 2-step tobit model to estimate, in the first stage, the determinants that explain whether Spanish innovative firms cooperate or not; and in the second stage the factors that affect the choice of partners. And third, we apply an ordered probit model to test the marginal effects of explanatory variables on the different partners. Here we contrast some of the most interesting empirical hypotheses of previous studies, and which emphasize the role of employees with degrees and PhDs in facilitating cooperative R&D between firms and scientific partners. JEL classification: O31, O33, O38. Key words: Determinants R&D cooperation, industry-university flows, PhD research workers.

A New Species of Kritskyia (Dactylogyridae, Ancyrocephalinae) Parasite of Urinary Bladder of Prochilodus lineatus (Prochilodontidae, Characiformes) from the Floodplain of the High Paraná River, Brazil

A new species of Kritskyia inhabits the urinary bladder of the "curimba", Prochilodus lineatus in the floodplain of the high Paraná river. The new species resembles others members of Kritskyia in the following features: haptor lacking anchors and with 14 hooks marginal, posterior male copulatory organ non articulated with the accessory piece and vagina a sclerotized tube. However, it differs from the known species mainly by the shape of the copulatory complex. This is the third endoparasitic monogenean species reported from freshwater Neotropical fish.

Analyse de facteurs déterminants de la substitution par des médicaments génériques en Suisse

Cadre de l'étude La part des dépenses de santé dans les budgets des pays occidentaux est importante et tend à croître depuis plusieurs décennies. Une des conséquences, notamment pour la Suisse, est une augmentation régulière des primes d'assurance maladie, dont l'impopularité incite les responsables politiques à trouver des stratégies de frein à la croissance des coûts de la santé. Les médicaments, qui contribuent notablement à l'augmentation de ces coûts, constituent l'une des cibles classiques d'interventions visant à une réduction des dépenses de santé. Le niveau de coûts des médicaments représente plus de 20% des dépenses de soins du domaine ambulatoire à la charge de l'assurance obligatoire des soins (AOS), soit une dépense annuelle de plus de 4 milliards de francs. Différentes mesures peuvent être utilisées par le gouvernement pour contenir cette facture à charge de la collectivité : baisse du prix des médicaments, limitation du nombre de produits remboursés par l'assurance de base et incitations à la concurrence sur les prix en autorisant les importations parallèles. Depuis que de plus en plus de brevets pour des médicaments sont arrivés à échéance, un autre angle d'attaque s'est concrétisé avec l'incitation à la prescription de médicaments génériques. Les génériques sont définis comme des produits thérapeutiques chimiquement identiques à des composés déjà utilisés, appelés médicaments originaux. En principe, une économie substantielle devrait pouvoir être réalisée sur les coûts totaux des médicaments si tous les génériques disponibles sur le marché étaient systématiquement prescrits par les professionnels et acceptés par les patients. Les résultats publiés par les caisses maladie et les offices fédéraux sont des estimations globales et les montants publiés par l'industrie pharmaceutique concernent l'ensemble du marché, incluant les médicaments utilisés dans les séjours hospitaliers, sont par ailleurs exprimés en prix de fabrique. De plus, aucune étude n'a tenu compte de la substituabilité des produits d'un point de vue pharmaceutique. L'objectif général de la thèse est d'évaluer aussi précisément que possible l'économie pouvant être encore réalisée dans le secteur ambulatoire en substituant aux médicaments originaux les produits génériques présents sur le marché et de caractériser plusieurs facteurs qui influencent la substitution générique. Pour cette étude, nous avons pu disposer de l'ensemble des factures pharmaceutiques de la caisse maladie CSS, pour tous ses assurés des cantons d'Argovie, du Tessin et de Vaud, soit plus de 169'000 assurés représentant les trois régions linguistiques de la Suisse. Les 1'341'197 prescriptions médicales qui ont été analysées concernent l'année 2003. C'est un moment critique dans l'histoire des génériques en Suisse, approprié pour établir un premier bilan après l'entrée en vigueur de la première mesure relative au droit de substituer octroyé en 2001 aux pharmaciens et, pour identifier idéalement les principaux déterminants de la substitution par les praticiens avant l'introduction de la quote-part différenciée en 2006. La présence d'un même principe actif n'est pas une condition suffisante pour permettre une substitution et pour ce travail des critères tenant compte des caractéristiques pharmaceutiques des produits ont été établis et appliqués pour valider la substituabilité des originaux par les génériques disponibles sur le marché. Ces critères concernent notamment le mode d'administration, le dosage et le nombre de doses dans l'emballage. L'étude a été réalisée selon deux approches, d'abord par une analyse descriptive sur l'ensemble de la population source pour estimer le marché des génériques et ensuite par une analyse statistique (régression logit multivariée) sur 173'212 prescriptions agrégées, qui concernent spécifiquement soit un générique soit un original substituable, pour caractériser les facteurs déterminants de la substitution générique. Résultats Dans l'ensemble de la population source, les génériques et les originaux substituables représentent 17,4% du marché en termes de coûts facturés, avec 3,4% de génériques et 14,0% d'originaux substituables ce qui correspond à un taux de substitution de 19,5%. En termes de dépenses, les substitutions génériques réalisées représentent une économie de 1,3% du total du marché étudié alors qu'il reste un potentiel notable d'économie par la substitution de 4,6%. Les taux de substitution sont très variables selon les cantons : 10,1% au Tessin, 29,0% pour le canton de Vaud et 35,8% pour Argovie. L'analyse univariée des 173'212 prescriptions de génériques ou d'originaux substituables, montre des taux de substitution plus élevés chez les patients jeunes et lorsqu'il y a d'importantes différences de prix entre les originaux et les génériques. Des taux de substitution peu élevés sont observés chez les patients les plus âgés et pour ceux qui ont des traitements médicamenteux complexes. Les patients ayant plus de 10 médicaments différents durant la même année, présentent une probabilité relative de substituer inférieure (-24%) par rapport aux patients ayant 6 à 10 médicaments différents dans l'année. Cependant, l'analyse multivariée montre que l'effet négatif sur le taux de substitution de l'âge combiné à la complexité des traitements n'excède pas 3%. Bien que le niveau de franchises et la participation financière à la quote-part soient liées à une augmentation de la prescription de génériques, leurs effets sont modérés pour les patients avec des franchises supérieures à 300 francs (effet marginal de 1%) et pour les patients qui n'ont pas atteint le plafond de participation (effet marginal de 2%). La différence de taux substitution entre les médecins hospitaliers et les spécialistes est diminuée de façon notable (effet marginal de -13%) et elle est cependant moins marquée avec les médecins généralistes (effet marginal de -3%). Les facteurs associés au marché ont une influence notable sur la substitution générique et des effets positifs sont observés avec l'augmentation de la taille du marché, du nombre de génériques pour un même original substituable et de l'économie relative entre l'original et le générique. Par contre, la diversification des formes galéniques et des tailles d'emballages au niveau de l'offre des médicaments originaux a des effets fortement négatifs sur la substitution générique (-7%). Le canton de domicile a aussi un impact notable sur la substitution et le canton du Tessin présente un taux plus bas (-26%) que le canton d'Argovie. Conclusion et perspectives Ce travail a montré qu'il y a encore un important potentiel d'économies à réaliser par la substitution générique, calculé à plus de 4% des dépenses pharmaceutiques prises en charge par l'AOS en ambulatoires. Une extrapolation à l'ensemble du marché suisse, qui doit être faite avec prudence, fait apparaître un potentiel d'économies de 127 millions pour les médicaments délivrés par les pharmacies en 2003. L'étude a mis en évidence un certain nombre de déterminants qui freinent la substitution générique, notamment la prescription par un médecin hospitalier. Sur ce point la prescription en DCI (dénomination commune internationale) pourrait favoriser la dispensation de génériques moins chers. Un taux de substitution plus faible est observé chez les patients âgés avec des traitements complexes. Ce constat peut être mis en relation avec la crainte d'avoir un traitement moins efficace ou moins bien supporté et les risques de confusion lors du passage d'un original substituable à un générique ou d'un générique à un autre générique. Sur ces éléments, l'indication claire et précise du nom de la substance, aussi bien sur les emballages des originaux substituables que sur ceux des génériques, pourrait rassurer les patients et diminuer les risques d'erreurs dans la prise des médicaments. Certaines précautions à prendre lors de la prescription de génériques sont reconnues, notamment pour les médicaments à faible marge thérapeutique, et des informations sur la bioéquivalence, régulièrement mises à jour et à disposition des professionnels, pourraient augmenter la confiance dans l'utilisation des génériques. Les industries pharmaceutiques préservent par différentes tactiques leurs parts de marché et notamment avec succès en introduisant de nouvelles formes galéniques juste avant l'expiration des brevets. Des directives complémentaires sur la fixation des prix pour le remboursement, en particulier l'introduction d'un prix de référence quelle que soit la forme galénique, pourraient diminuer l'effet de barrage des médicaments originaux. Les incitations économiques, telles que la franchise et les participations sont efficaces si l'on considère l'impact sur les taux de substitution. Leur effet global reste toutefois modeste et il serait nécessaire de mesurer concrètement l'impact de l'introduction en 2006 de la quote-part différenciée. Les différences de prix entre les originaux et les génériques exigées à 50% pour les gros marchés, c'est-à-dire de plus de 16 millions, devraient aussi avoir un impact qu'il serait opportun de mesurer.

Caballerocotyla lenti n. sp., a capsalid monogenean from Auxis thazard (Scombridae) from off the southeastern coast of Brazil

Caballerocotyla lenti n. sp. (Monogenea: Capsalidae), recovered from the gills of Auxis thazard (Lacépède) captured off the coast of Rio de Janeiro, Brazil, is described using light and scanning electron microscopy. The new species is characterized by: a tegument with 2-5 rows of dorso-marginal, unicuspid spines; 53-54 round testes; a constricted pharynx with numerous papillae on its border; and a haptor with a plicate marginal border, a central polygonal area and seven complete septa. C. manteri (Price, 1951) and C. gouri Chauhan, 1953 sensu Murugesh (1995) are figured and commented upon.

The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans.

Aggregation-prone polyglutamine (polyQ) expansion proteins cause several neurodegenerative disorders, including Huntington disease. The pharmacological activation of cellular stress responses could be a new strategy to combat protein conformational diseases. Hydroxylamine derivatives act as co-inducers of heat-shock proteins (HSPs) and can enhance HSP expression in diseased cells, without significant adverse effects. Here, we used Caenorhabditis elegans expressing polyQ expansions with 35 glutamines fused to the yellow fluorescent protein (Q35-YFP) in body wall muscle cells as a model system to investigate the effects of treatment with a novel hydroxylamine derivative, NG-094, on the progression of polyQ diseases. NG-094 significantly ameliorated polyQ-mediated animal paralysis, reduced the number of Q35-YFP aggregates and delayed polyQ-dependent acceleration of aging. Micromolar concentrations of NG-094 in animal tissues with only marginal effects on the nematode fitness sufficed to confer protection against polyQ proteotoxicity, even when the drug was administered after disease onset. NG-094 did not reduce insulin/insulin-like growth factor 1-like signaling, but conferred cytoprotection by a mechanism involving the heat-shock transcription factor HSF-1 that potentiated the expression of stress-inducible HSPs. NG-094 is thus a promising candidate for tests on mammalian models of polyQ and other protein conformational diseases.

Trends in self-reported prevalence and management of hypertension, dyslipidaemia and diabetes in adults in Switzerland, 1992-2007

Purpose: to assess the trends of self-reported prevalence of cardiovascular risk factors (CV RFs: hypertension, dyslipidaemia, diabetes) and their management for period 1992 to 2007 in the Swiss population. Methods: four National health interview surveys conducted between 1992 and 2007 in representative samples of the Swiss population (63,782 subjects overall). Self-reported CV RFs prevalence, treatment and controllevels were computed after weighting. Weights were calculated by raking ratio such that the marginal distribution of the weighted totals conforms to the marginal distribution of the targeted population. Multivariate analysis adjusted on age, sex, education, nationality and SMI was conducted using logistic regression. Results: prevalence of ail CV RFs increased between 1992 and 2007, see table. Although the self-reported prevalence of treatment among subjects with CV RFs increased, and this was confirmed by multivariate analysis: OR for hypocholesterolaemic treatment relative to 1992: 0.64 [0.52-0.78]; 1.39 [1.18-1.65] and 2.00 [1.69-2.36] for 1997, 2002 and 2007, respectively. Still, in 2007, circa 40% of hypertensive, 60% of dyslipidaemic and 50% of diabetic subjects weren't treated. Conversely, an adequate control of CV RFs was reported by treated subjects, with an increase during the study period. This increase was confirmed by multivariate analysis (not shown). Conclusion: the self-reported prevalence of hypertension, dyslipidaemia and diabetes increased between 1992 and 2007 in the Swiss population. Despite a good control of treated subjects, still a significant percentage of subjects with CV RFs are not treated.

Improved surgical technique for laparoscopic Roux-en-Y gastric bypass reduces complications at the gastrojejunostomy.

Roux-en-Y gastric bypass (RYGBP) is one of the most commonly performed bariatric procedures for morbidly obese patients. It is associated with effective long-term weight loss, but can lead to significant complications, especially at the gastrojejunostomy (GJS). All the patients undergoing laparoscopic RYGBP at one of our two institutions were included in this study. The prospectively collected data were reviewed retrospectively for the purpose of this study, in which we compared two different techniques for the construction of the GJS and their effects on the incidence of complications. In group A, anastomosis was performed on the posterior aspect of the gastric pouch. In group B, it was performed across the staple line used to form the gastric pouch. A 21-mm circular stapler was used in all patients. A total of 1,128 patients were included between June 1999 and September 2009-639 in group A and 488 in group B. Sixty patients developed a total of 65 complications at the GJS, with 14 (1.2%) leaks, 42 (3.7%) strictures, and 9 (0.8%) marginal ulcers. Leaks (0.2% versus 2%, p = 0.005) and strictures (0.8% versus 5.9%, p < 0.0001) were significantly fewer in group B than in group A. Improved surgical technique, as we propose, with the GJS across the staple line used to form the gastric pouch, significantly reduces the rate of anastomotic complications at the GJS. A circular 21-mm stapler can be used with a low complication rate, and especially a low stricture rate. Additional methods to limit complications at the GJS are probably not routinely warranted.

Biased gene conversion and GC-content evolution in the coding sequences of reptiles and vertebrates.

Mammalian and avian genomes are characterized by a substantial spatial heterogeneity of GC-content, which is often interpreted as reflecting the effect of local GC-biased gene conversion (gBGC), a meiotic repair bias that favors G and C over A and T alleles in high-recombining genomic regions. Surprisingly, the first fully sequenced nonavian sauropsid (i.e., reptile), the green anole Anolis carolinensis, revealed a highly homogeneous genomic GC-content landscape, suggesting the possibility that gBGC might not be at work in this lineage. Here, we analyze GC-content evolution at third-codon positions (GC3) in 44 vertebrates species, including eight newly sequenced transcriptomes, with a specific focus on nonavian sauropsids. We report that reptiles, including the green anole, have a genome-wide distribution of GC3 similar to that of mammals and birds, and we infer a strong GC3-heterogeneity to be already present in the tetrapod ancestor. We further show that the dynamic of coding sequence GC-content is largely governed by karyotypic features in vertebrates, notably in the green anole, in agreement with the gBGC hypothesis. The discrepancy between third-codon positions and noncoding DNA regarding GC-content dynamics in the green anole could not be explained by the activity of transposable elements or selection on codon usage. This analysis highlights the unique value of third-codon positions as an insertion/deletion-free marker of nucleotide substitution biases that ultimately affect the evolution of proteins.

The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice.

BackgroundMutations in TNFRSF13B, the gene encoding transmembrane activator and calcium modulator cyclophilin ligand interactor (TACI), are found in 10% of patients with common variable immunodeficiency. However, the most commonly detected mutation is the heterozygous change C104R, which is also found in 0.5% to 1% of healthy subjects. The contribution of the C104R mutation to the B-cell defects observed in patients with common variable immunodeficiency therefore remains unclear.ObjectiveWe sought to define the functional consequences of the C104R mutation on B-cell function.MethodsWe performed in vitro studies of TACI C104R expression and signaling. A knock-in mouse with the equivalent mutation murine TACI (mTACI) C76R was generated as a physiologically relevant model of human disease. We examined homozygous and heterozygous C76R mutant mice alongside wild-type littermates and studied specific B-cell lineages and antibody responses to T cell-independent and T cell-dependent challenge.ResultsC104R expression and ligand binding are significantly diminished when the mutant protein is expressed in 293T cells or in patients' cell lines. This leads to defective nuclear factor κB activation, which is proportionally restored by reintroduction of wild-type TACI. Mice heterozygous and homozygous for mTACI C76R exhibit significant B-cell dysfunction with splenomegaly, marginal zone B-cell expansion, diminished immunoglobulin production and serological responses to T cell-independent antigen, and abnormal immunoglobulin synthesis.ConclusionsThese data show that the C104R mutation and its murine equivalent, C76R, can significantly disrupt TACI function, probably through haploinsufficiency. Furthermore, the heterozygous C76R mutation alone is sufficient to disturb B-cell function with lymphoproliferation and immunoglobulin production defects.

Evaluation of five screening tests licensed in Argentina for detection of hepatitis C virus antibodies

This study was conducted to compare among the most recent generation of five screening tests licensed in Argentina, in order to evaluate which of the tests has the best sensitivity for detection of antibodies against hepatitis C virus (HCV). The tests analyzed were: Detect-HCV™ (3.0) Biochem ImmunoSystems, Canada; Hepatitis C EIA Wiener Lab., Argentina; Equipar HCV Ab, Italy; Murex HCV 4.0, UK and Serodia-HCV particles agglutination test, Japan. The results obtained showed high discrepancy between the different kits used and show that some of the tests assessed have a low sensitivity for anti-HCV detection in both chronic infections and early seroconversion, and indicate that among the commercially available kits in Argentina, Murex HCV 4.0 (UK) and Serodia-HCV particles agglutination test (Japan) have the best sensitivity for HCV screening. Although the sensitivity of the assays is the first parameter to be considered for blood screening, more studies should be carried out to assess the specificity of such assays.

Tethyan margins in space and time

Rifting processes, leading to sea-floor spreading, are characterized by a sequence of events: transtensive phase of extension with syn-rift volcanism; simple shear extension accompanied by lithospheric thinning and asthenospheric up-welling and thermal uplift of the rift shoulder and asymmetric volcanism. The simple shear model of extension leads to an asymmetric model of passive margin: a lower plate tilted block margin and an upper plate flexural, ramp-like margin- Both will be affected by thermal contraction and subsidence, starting soon after sea-floor spreading. Based on these actualistic models Tethyan margins are classified as one type or the other. Their evolution from the first transtensional phase of extension to the passive margin stage are analyzed. Four main rifting events are recognized in the Tethyan realm: an episode of lower Paleozoic events leading to the formation of the Paleotethys; a Late Paleozoic event leading to the opening of the Permotethys and East Mediterranean basin: an early Mesozoic event leading to the opening of the Pindos Neotethys and a Jurassic event related to the opening of the Alpine/Atlantic Neotethys. Type margins are given as example of each rifting event: -Northern Iran (Alborz) as a type area for the Late Ordovician to Silurian rifting of Paleotethys. -Northern India and Oman for the Late Carboniferous to early Permian rifting of Permotethys. -The East Mediterranean (Levant, Tunisia) as a Late Carboniferous rifting event. -The Neotethyan rifting phases are separated in two types: an eastern Pindos system found in Turkey and Greece is genetically linked to the Permotethys with a sea-floor spreading delayed until middle Triassic: a western Alpine system directly linked to the opening of the central Atlantic is characterized by a Late Triassic transtensive phase, an early to Middle Liassic break-away phase and. following sea-floor spreading, a thermal subsidence phase starting in Dogger. Problems related to the closure of the Paleozoic oceanic domains are reviewed. A Late Permian, early Triassic phase of `'docking'' between an European accretionary prism (Chios) and a Paleotethyan margin is supported by recent findings in the Mediterranean area. Back-arc rifting within the European active margin led to the formation of marginal seas during Permian and Triassic times and will contribute to the closure of the Paleozoic oceans.

First evaluation of human sperm quality in various geographic regions of Switzerland

A decline in human sperm quality and quantity has been reported in numerous Western countries. This observation was also accompanied by an increase in urogenital malformations. The need for epidemiological studies dealing with unbiased populations in order to understand the causes of these observations is obvious. In Switzerland, the large majority of young men are asked to attend a military camp to be drafted into the army. A few weeks before this camp, conscripts were contacted and invited to participate in a large national study on semen quality. The participation was totally voluntary and anonymous. From September 2005 to June 2007, 770 volunteers filled out a questionnaire, underwent a clinical examination and provided sperm, blood and urine samples. Using self-rated health assessments, the observed cohort could be considered as healthy and no testicular cancer was found. Moreover, the testicular volumes, measured using Prader's orchidometry and ultrasonography, were comparable to those already published for young male populations. The median sperm concentration was 47 x 10(6)/ml, which is close to the concentration reported in Denmark, known to have the highest incidence of testicular cancer in Europe. Statistically significant differences were observed between regions with a lower sperm concentration for men residing in the Alps (43 x 10(6)/ml) and in the Zurich area (36 x 10(6)/ml) compared to men from West Plateau (54 x 10(6)/ml) and from the Jura (54 x 10(6)/ml). Such a regional discrepancy could be related to environmental factors, including endocrine disruptors. In order to confirm such regional differences more volunteers from the already studied regions should be studied and other parts of the country should be investigated. The rather low sperm concentration of Swiss young volunteers should be considered as a national health issue and investigated further.

The significance of pre-existing minority Y181C mutations on virological failure of NNRTI-based, first-line antiretroviral therapy

Background: Reduced re'nal function has been reported with tenofovir disoproxil fumarate (TDF). It is not clear whether TDF co-administered with a boosted protease inhibitor (PI) leads to a greater decline in renal function than TDF co-administered with a non-nucleoside reverse transcriptase inhibitor (NNRTI).Methods: We selected ail antiretroviral therapy-naive patients in the Swiss HIV Cohort Study (SHCS) with calibrated or corrected serum creatinine measurements starting antiretroviral therapy with TDF and either efavirenz (EFV) or the ritonavir-boosted PIs, lopinavir (LPV/r) or atazanavir (ATV/r). As a measure of renal function, we used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to estimate the glomerular filtration rate (eGFR). We calculated the difference in eGFR over time between two therapies using a marginal model for repeated measures. In weighted analyses, observations were weighted by the product of their point of treatment and censoring weights to adjust for differences both in the sort of patients starting each therapy and in the sort of patients remaining on each therapy over time.Results: By March 2011, 940 patients with at least one creatinine measurement on a first therapy with either TDF and EFV (n=484), TDF and LPVlr (n=269) or TDF and ATV/r (n=187) had been followed for a median of 1. 7, 1.2 and 1.3 years, respectively. Table 1 shows the difference in average estimated GFR (eGFR) over time since starting cART for two marginal models. The first model was not adjusted for potential confounders; the second mode! used weights to adjust for confounders. The results suggest a greater decline in renal function during the first 6 months if TDF is used with a PI rather than with an NNRTI, but no further difference between these therapies after the first 6 months. TDF and ATV/r may lead to a greater decline in the first 6 months than TDF and LPVlr.Conclusions: TDF co-administered with a boosted PI leads to a greater de cline in renal function over the first 6 months of therapy than TDF co-administered with an NNRTI; this decline may be worse with ATV/r than with LPV/r.

High proportion of hepatitis C virus genotypes 1 and 3 in a large cohort of patients from Southern Brazil

Hepatitis C virus (HCV) isolates have been divided into six genotypes (1 to 6). The duration of hepatitis C standard treatment is 48 weeks for patients infected with HCV genotype 1 vs 24 weeks for those infected with genotypes 2 and 3. A total of 1544 HCV isolates from chronic patients living in the southern Brazilian states of Rio Grande do Sul (RS, n = 627) and Santa Catarina (SC, n = 917) were genotyped by restriction fragment length polymorphism (RFLP) of polymerase chain reaction (PCR) products. In RS, 338 (53.9%; 95% CI 50.0 - 57.8%), 34 (5.4%; 95% CI 3.8 - 7.4%) and, 255 (40.7%; 95% CI 36.9 - 44.6%) samples were from genotypes 1, 2, and 3, respectively. In SC, 468 (51%; 95% CI 47.8 - 54.2%), 26 (2.9%; 95% CI 1.9 - 4.1%) and, 423 (46.1%; 95% CI 42.9 - 49.3%) samples were from genotypes 1, 2, and 3, respectively. Genotyping results were confirmed by direct nucleotide sequencing of PCR products derived from 68 samples, without any discrepancy between PCR-RFLP and nucleotide sequencing methods. In conclusion, almost half of the hepatitis C patients from South of Brazil are infected by genotypes 2 and 3 and, these results have important consequential therapeutic implications as they can be treated for only 24 weeks, not 48.